These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6795369)

  • 1. Prevention of posttransfusion hepatitis: cost-effective or not?
    Iber FL
    JAMA; 1981 Nov; 246(20):2356. PubMed ID: 6795369
    [No Abstract]   [Full Text] [Related]  

  • 2. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alanine aminotransferase and posttransfusion hepatitis.
    Lacher DA
    JAMA; 1987 Feb; 257(8):1048. PubMed ID: 3100827
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum bile acids and alanine aminotransferase concentrations. Comparison of efficacy as indirect means of identifying carriers of non-A, non-B hepatitis agents and of onset, severity, and duration of posttransfusion non-A, non-B hepatitis in recipients.
    Mishler JM; Barbosa L; Mihalko LJ; McCarter H
    JAMA; 1981 Nov; 246(20):2340-4. PubMed ID: 6795368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate testing for non-A, non-B hepatitis.
    Anderson CC; Contreras M; Barbara JA; Mijovic V
    Lancet; 1987 Apr; 1(8538):912. PubMed ID: 2882303
    [No Abstract]   [Full Text] [Related]  

  • 6. Reducing hepatitis by testing blood for alanine aminotransferase.
    Kahn RA
    N Engl J Med; 1983 Apr; 308(14):844-5. PubMed ID: 6403860
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum alanine aminotransferase (ALT) assay and incidence of posttransfusion non-A,non-B hepatitis.
    Barcena Marugan R; Zamora C; Moreno A; Erdozain Sosa JC; Perez Hernandez F; Lopez San Roman A
    Transfusion; 1989 Oct; 29(8):751. PubMed ID: 2508279
    [No Abstract]   [Full Text] [Related]  

  • 8. Nationwide ALT testing to prevent non-A, non-B hepatitis still on hold.
    Cowart VS
    JAMA; 1981 Dec; 246(24):2791-2. PubMed ID: 6796706
    [No Abstract]   [Full Text] [Related]  

  • 9. [Public Health Council advisory: prevention of post-transfusion non-A non-B hepatitis; is application of a surrogate test a missed station?].
    Brandt KH
    Ned Tijdschr Geneeskd; 1989 Nov; 133(45):2212-4. PubMed ID: 2509949
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of a table-top analyzer for predonation screening for alanine aminotransferase--a cost-effective approach?
    Saxena S; Endahl GL; Shulman IA
    Am J Clin Pathol; 1988 Sep; 90(3):296-9. PubMed ID: 3137804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-A, non-B hepatitis surrogate testing of blood donations.
    Lancet; 1987 Jun; 1(8546):1366-7. PubMed ID: 2884466
    [No Abstract]   [Full Text] [Related]  

  • 12. [Screening of blood donors for the prevention of non-A, non-B hepatitis].
    Seidl S
    Dtsch Med Wochenschr; 1983 Jan; 108(4):123-4. PubMed ID: 6402351
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of a needle stick.
    Miller DJ
    J Clin Gastroenterol; 1979 Sep; 1(3):251-8. PubMed ID: 95411
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening of blood donors.
    Carlson RE; Hering PJ
    JAMA; 1981 Sep; 246(11):1195. PubMed ID: 6790735
    [No Abstract]   [Full Text] [Related]  

  • 15. [Contribution to the task of reducing the incidence of post transfusion non-A, non-B hepatitis].
    Hernández Sánchez MC; Vila Enriquez P; Alvarez Hernández M
    Sangre (Barc); 1989 Jun; 34(3):248-9. PubMed ID: 2503897
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevention of non-A non-B hepatitis in Guadeloupe].
    Fest T; Gordien E; Neubauer J; Citadelle E; Agis F
    Rev Fr Transfus Hemobiol; 1989 Dec; 32(6):483-4. PubMed ID: 2517013
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing the incidence of non-A,non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations.
    Hornbrook MC; Dodd RY; Jacobs P; Friedman LI; Sherman KE
    N Engl J Med; 1982 Nov; 307(21):1315-21. PubMed ID: 6813736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concerns about ALT testing.
    Kosmin M
    Transfusion; 1982; 22(6):535-7. PubMed ID: 6815842
    [No Abstract]   [Full Text] [Related]  

  • 19. Posttransfusion hepatitis: clinical features, risk and donor testing.
    Alter HJ
    Prog Clin Biol Res; 1985; 182():47-61. PubMed ID: 3929262
    [No Abstract]   [Full Text] [Related]  

  • 20. [Currently available means for the prevention of post-transfusion hepatitis and criteria for their application].
    Bedarida G; Cambiè G; D'Agostino F; Sterza G
    Ric Clin Lab; 1984; 14 Suppl 1():37-60. PubMed ID: 6429830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.